HB413 Alabama 2010 Session

Summary

Primary Sponsor

Rod Scott

Democrat

Co-Sponsors

Jim BartonJim McClendonJamie IsonSteve McMillanChad FincherJoe FaustHarry ShiverJimmy MartinJoe HubbardGerald H. AllenDickie DrakeJack WilliamsMike BallVictor GastonJay LoveSteve ClouseBarry MaskElaine BeechMary Sue McClurkinWarren BeckAlan BootheRichard J. LairdCharles O. NewtonAllen TreadawaySpencer CollierRobert BentleyGreg WrenMicky HammonPhil WilliamsDavid GrimesHoward SanderfordDuwayne BridgesGregory CanfieldMac McCutcheonAlan HarperMike MillicanJody LetsonMike CurtisYvonne KennedyOliver RobinsonThad McClammyRalph HowardPebblin W. WarrenJames O. GordonDemetrius C. NewtonYusuf SalaamRandy HinshawTerry SpicerLaura HallBill J. DukesWilliam “Bill” M. BeasleyMike HillH. Mac GipsonRandy DavisCraig FordElwyn ThomasJohnny Mack MorrowPatricia ToddJohn RobinsonJames C. FieldsWilliam E. ThigpenButch TaylorHenry A. WhiteTommy ShererJames E. BuskeySteve HurstTammy Irons

Session

Regular Session 2010

Title

Ephedrine, pseudoephedrine, and phenylpropanolamine, State Board of Health required to classify as controlled substances, exemptions, removed from list of precursor chemicals maintained by State Board of Pharmacy, Secs. 20-2-20, 20-2-181 am'd.

Summary

HB413 would make ephedrine, pseudoephedrine, and phenylpropanolamine Schedule III controlled substances, sold by prescription, with a mechanism to exempt products designed to prevent meth production and to revoke those exemptions.

What This Bill Does

The State Board of Health would classify the three substances as Schedule III controlled substances. It could exempt a product containing these substances from control if the product is effectively formulated to prevent conversion to methamphetamine, and it could revoke that exemption after notification from the Department of Public Safety. The bill also outlines the factors the Board must consider when deciding to control a substance and requires coordination with federal scheduling rules. It adds a requirement for the Board of Pharmacy to designate listed precursor chemicals (including these substances) and to follow procedures to add or delete chemicals, with emergency revocation authority and a defined notification process. The act becomes effective on the first day of the third month after passage.

Who It Affects

• Consumers who buy or use products containing ephedrine, pseudoephedrine, or phenylpropanolamine may need prescriptions, and some products could be exempt if they are formulated to prevent meth production.
• Pharmacies, manufacturers, and distributors that sell or produce products containing these substances must comply with scheduling rules, may seek exemptions, and must follow precursor chemical listing and related regulatory procedures.

Key Provisions

• Classify ephedrine, pseudoephedrine, and phenylpropanolamine as Schedule III controlled substances, requiring prescription for sale.
• Authorize the State Board of Health to exempt from classification any product containing these substances if it is effectively formulated to prevent conversion to methamphetamine, with emergency revocation possible after notice from the Department of Public Safety.
• Require the Board of Health to consider specific factors (abuse potential, pharmacological effects, current knowledge, abuse history, public health risk, dependence potential, and whether it is a precursor) when deciding to control a substance, and to issue a controlling rule if abuse is found.
• Coordinate with federal law so that if a substance is designated or re-designated under federal law, the Board will similarly control it after 30 days unless it objects, with a hearing and published reasons if objections occur.
• Require the Board of Pharmacy to designate listed precursor chemicals by rule (including ephedrine, pseudoephedrine, and phenylpropanolamine) and to follow procedures for adding or deleting substances, with emergency revocation authority and an objection/hearing process; until rules are adopted, certain chemicals are deemed listed precursors.

AI-generated summary using openai/gpt-5-nano on Feb 25, 2026. May contain errors — refer to the official bill text for accuracy.

Subjects

Controlled Substances